Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (191)	1/13/2005 4:26:56 AM
From: tuck	Read Replies (1) \| Respond to of 802

>>I would imagine that in order for PEG3 to be utilized commercially for p53 and mda7, they would need to do some licensing from INGN?<< Huh? What "they" are we talking about? We both understand that INGN controls the gene therapy applications of p53 and MDA-7, so sure, folks wanting to use it commercially for gene therapy will have to come to INGN. It is not at all clear to me who controls the PEG-3 promoter IP, INGN or Columbia. Does Fisher's lab license everything to INGN? Is there some long standing agreement that's buried in some exhibit to the S-1 that covers technology transfer from there to INGN that PEG-3 would be a part of? That's all I wanted to know. I agree that if INGN does not control PEG-3 and someone wants to use it in conjunction with MDA-7 or p53, as the PNAS paper happens to demonstrate because that happens to be an area of interest for Fisher, they will have to license the p53 or MDA-7 part from INGN. Did I say that enough ways to clarify my question (hope I didn't make it worse)? Who owns PEG-3? Cheers (and goodnight), Tuck